Sep
06, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Endo Pharmaceuticals
Inc revealed on Thursday that the US Food and Drug Administration (FDA)
has accepted for review the complete response submission for its new
drug application (NDA) for its long-acting testosterone undecanoate
injection, AVEED.
In conjunction with the FDA's
acceptance, the company's NDA has been assigned a new Prescription Drug
User Fee Act (PDUFA) action date of 28 February 2014.
The company added AVEED is being studied for men that are diagnosed with hypogonadism.
Endo Pharmaceuticals Inc is healthcare company and a subsidiary of Endo Health Solutions Inc (nasdaqgs:ENDP).
No comments:
Post a Comment
All coments are moderated. Obscenities get you tossed out. Do not leave personal info incomments, but professional contact info is accepted.